Montréal, August 15, 2022

Nova Biologiques, a biotechnology company developing novel vaccines and biologic therapeutic candidates, is pleased to formally announce the launch of its PF-D-Trimer™ SARS-CoV-2 prophylactic vaccine pre-clinical Investigator-Initiated Trial (IIT). In alignment with Nova Biologiques mission to accelerate the development and application of new vaccines, the IIT will provide proof-of-concept data and expanded product knowledge regarding safety and efficacy. The results from the studies are expected by the end of 2022.

The TD™ Trimer-Domain technology platform is a product development platform for the creation of novel vaccines and biologic therapies.  Nova Biologiques has developed and markets applications related to the TD™ Trimer-Domain, the most recent being the development of the prophylactic vaccine PF-D-Trimer™ for protection against SARS-CoV-2.

Montréal, October 1, 2022

Nova Biologiques, a biotechnology company developing novel vaccines and biologic therapeutic candidates, announces that the patent application filed with the Intellectual Property Office of the People’s Republic of China relating to the TD™ Trimer-Domain has been accepted and the patent has been issued.

This patent describes not only the elements of the system that makes up the invention but also the resulting protein purification method, according to which it is possible to purify any protein in a simple and rapid step.

This is another opportunity for Nova Biologiques to expand its portfolio of intellectual properties and thus solidify its position as an innovative company.

The TD™ Trimer-Domain technology platform is a product development platform for the creation of novel vaccines and biologic therapies.  Nova Biologiques has developed and markets applications related to the TD™ Trimer-Domain, the most recent being the development of the prophylactic vaccine PF-D-Trimer™ for protection against SARS-CoV-2, currently in an Investigator-Initiated Trial (IIT).

Nova Biologiques Announces Peer-Reviewed Publication in npj Vaccines of Preclinical Data for SARS-CoV-2 Vaccine Candidate Showing 100% Protection.

Montreal, QC, Canada. March 16, 2023 Nova Biologiques announced today the publication of a peer-reviewed animal efficacy study of its SARS-CoV-2 subunit vaccine. The study was published in npj Vaccines.
Nova Biologiques’ vaccine, PF-D-Trimer, the pre-fusion trimerized Delta spike protein, is highly expressed in Chinese hamster ovary (CHO) cells. The antigen is purified by a rapid one-step anti-Trimer Domain monoclonal antibody immunoaffinity process and prepared as a vaccine formulation with an adjuvant. Immunogenicity studies have shown that this vaccine candidate induces robust immune responses in mouse, rat and Syrian hamster models. It also protects K18-hACE2 transgenic mice in a homologous viral challenge. Neutralizing antibodies induced by this vaccine show cross-reactivity against the ancestral WA1, Delta and several Omicrons, including BA.5.2. The formulated PF-D Trimer is stable for up to six months without refrigeration. The Trimer Domain platform was proven to be a key technology in the rapid production of PF-D-Trimer vaccine and may be crucial to accelerate the development and accessibility of updated versions of SARS-CoV-2 vaccines.
Contact:
Nova Biologiques Inc.
[email protected]